Dl-3-n-butylphthalide attenuates mouse behavioral deficits to chronic social defeat stress by regulating energy metabolism via AKT/CREB signaling pathway

Wei Wang1,2,3, Ting Wang1,2,4, Shunjie Bai1,2,5, Zhi Chen1,2, Xunzhong Qi1,2 and Peng Xie1,2,3,4,6,7

Abstract
Major depressive disorder (MDD) is a severe mental disorder associated with high rates of morbidity and mortality. Current first-line pharmacotherapies for MDD are based on enhancement of monoaminergic neurotransmission, but these antidepressants are still insufficient and produce significant side-effects. Consequently, the development of novel antidepressants and therapeutic targets is desired. Dl-3-n-butylphthalide (NBP) is a compound with proven efficacy in treating ischemic stroke, yet its therapeutic effects and mechanisms for depression remain unexplored. The aim of this study was to investigate the effect of NBP in a chronic social defeat stress model of depression and its underlying molecular mechanisms. Here, we examined depression-related behavior and performed a targeted metabolomics analysis. Real-time quantitative polymerase chain reaction and western blotting were used to examine key genes and proteins involved in energy metabolism and the AKT/cAMP response element-binding protein (CREB) signaling pathway. Our results reveal NBP attenuates stress-induced social deficits, anxiety-like behavior and despair behavior, and alters metabolite levels of glycolysis and tricarboxylic acid (TCA) cycle components. NBP affected gene expression of key enzymes of the TCA cycle, as well as protein expression of p-AKT and p-CREB. Our findings provide the first evidence showing that NBP can attenuate stress-induced behavioral deficits by modulating energy metabolism by regulating activation of the AKT/CREB signaling pathway.

Introduction
Major depressive disorder (MDD) is an increasingly common psychiatric disorder that globally affects > 300 million people of all ages, and is also one of the leading causes of disability worldwide1,2. Pharmacotherapy is the primary choice for medical management of MDD. Classes of first-line antidepressant medications have been approved to reduce depressive symptoms, but it often takes weeks to produce a measurable benefit. Further, some drugs produce significant side-effects including fatigue, weight gain, nausea, headache, and sexual dysfunction3–5. Hence, the search for new treatments of MDD has always been a focus in biomedical research, with investigation of alternative treatments urgently needed to reduce the heavy burden of MDD on patients and society.

Increasing evidence suggests the involvement of energy metabolism pathways in MDD. We have previously shown dysfunction in energy metabolism in most brain regions and plasma in a rodent model of chronic mild stress6–9. Corroboratively, our recent study demonstrated the disruption of glucose energy metabolism in naturally occurring depression in cynomolgus monkeys and...
patients with MDD. At present, energy metabolism abnormalities in depression mainly include: (1) dysfunction of nutrient utilization in glycolysis/gluconeogenesis; (2) mitochondrial damage in constituents of the tricarboxylic acid (TCA) cycle; and (3) functional damage in the mitochondrial respiratory chain. Minimizing perturbations in energy metabolism may prevent development of depression, although antidepressants with the relevant properties are not yet clinically available. Thus, targeting energy metabolism pathways may be important for identifying novel antidepressant drugs.

Dl-3-n-butylphthalide (NBP) represents a family of compounds initially isolated from the seeds of *Apium graveolens* Linn (celery), which are approved for the treatment of acute ischemic stroke. Previous studies have shown that NBP improves stroke outcome by protecting mitochondrial function and improving energy metabolism. NBP may be effective in treating neurological disorders beyond the management of stroke. Moreover, recent studies have shown that by promoting energy metabolism, NBP may be effective in treating neurological disorders beyond the management of stroke. NBP exhibits protective effects against mitochondrial damage by inhibiting amyloid β (Aβ)-induced mitochondrial dysfunction, whereas Aβ induces active caspase-3, caspase-9, and cytochrome c expression in Alzheimer’s disease.

NBP ameliorates SH-SY5Y cell survival against caspase-9, and cytochrome c expression in Alzheimer gene expression and the mitochondrial membrane gralism. Mitochondrial function and improving energy metabolism were shown that NBP improves stroke outcome by protecting mitochondrial function and improving energy metabolism. NBP may be effective in treating neurological disorders beyond the management of stroke. NBP exhibits protective effects against mitochondrial damage by inhibiting amyloid β (Aβ)-induced mitochondrial dysfunction, whereas Aβ induces active caspase-3, caspase-9, and cytochrome c expression in Alzheimer’s disease.

**Materials and methods**

**Animals**

Healthy male C57BL/6 J mice (aged 7–8 weeks and weighing 20–23 g, *N* = 40) and male CD1 mice (aged 18–20 weeks and weighing 35–40 g, *N* = 90) were purchased from the Experimental Animal Centre of Chongqing Medical University (Chongqing, China). During the entire study, the mice were maintained in a temperature and humidity controlled room (21–22°C, 55 ± 5%) under a 12 h light/dark cycle with access to food and water freely. The study were approved by the Ethics Committee of Chongqing Medical University.

**Drug treatment**

All mice were randomly divided into control with placebo group (CON + PLA group) and CSDS with placebo group (CSDS + PLA group) and CSDS with NBP group (CSDS + NBP group) after 1 week of adaptive feeding. The CON + PLA group (*N* = 12) and CSDS + PLA group (*N* = 15) were treated with soybean oil, and the CSDS + NBP group (*N* = 13) was treated with NBP (60 mg/kg, diluted in soybean oil) daily. Mice received intragastric administration daily in a volume of 200 µl between 14:00 PM and 14:30 PM for 24 days.

**CSDS**

An established CSDS protocol was used to induce depressive-like behavior in mice. The CSDS procedure in the study was performed as previously reported. The protocol is beginning with the selection of aggressive CD1. Forty-one CD1 mice with appropriate characteristics as described below were selected from 90 CD1. There are two criteria for screening the aggressive behavior of CD1 mice as below: first, CD1 mice must have attacked the C57BL/6 J mice at last 2 consecutive days in the period of 3 days of screening; second, the initial attack on C57BL/6 J must be < 60 seconds during each
180-second screening process per day. House 41 CD1 mice singly in the one side of defeated cages as “resident” to habituate to their new colony facility for 7 days prior to the start of defeat sessions. During the 10-day defeat period, a C57BL/6J mouse as “intruder” was introduced into the home cage of a novel aggressive “resident” for 10 min every day. After the physical stress, the C57BL/6J mouse was immediately transferred to the opposite compartment, which was separated by a perforated transparent plexiglass divider for 24 h continued sensory contact. Mice were excluded from the study if repeated defeats lead to open wounds on the C57BL/6J mice that exceeded 1 cm in length.

**Social interaction test**
Social interaction (SI) test was used to detect the social avoidance behavior. Twenty-four hours after the last stress session, the C57BL/6J mouse was housed individually to perform the test, which was proceeded by placing mice in an open field box (44 cm × 44 cm × 30 cm) with a perforated plastic box (10 cm × 7 cm × 18 cm) located at one end and was carried out under the condition of red light. In first detection, the perforated plastic box was empty. The movement of the C57BL/6J mice was videotaped (Ethovision, Noldus, The Netherlands) for 2.5 min. In second detection, an unfamiliar CD1 was placed in the perforated plastic box and the movement of the C57BL/6J mice was also recorded for 2.5 min. The SI ratio = time spent in an interaction zone with a CD1 mouse/time spent in an interaction zone without a CD1 mouse. Mice with SI ratio > 1 were defined as “resilient” and mice with SI ratio below 1 were defined as “susceptible”.

**Behavioral testing**
After drug treatment, a series of behavioral tests were performed during day time (light-on periods) under conditions of dim light and low noise.

**Sucrose preference test**
The sucrose preference test (SPT) was applied to assess the anhedonia response in rodents. Mice were habituated to 1% sucrose water for 3 days prior to the test. After 24 h deprivation of water and food, mice were provided with 1% sucrose water and pure water. The consumption levels were measured after 24 h testing. Sucrose preference (%) = (sucrose water intake/(sucrose water intake + pure water intake)) × 100.

**Three-chambered interaction test**
The three-chambered interaction test was used to assess social impairment phenotypes in rodents. The test was proceeded in a rectangular, three-chambered box (60 cm × 40 cm × 30 cm), which was divided by two plastic clapboard with a small hole to create optimum entryways and encourage exploration across chamber openings, and two perforated plastic boxes (10 cm × 7 cm × 18 cm) was also required. The testing procedure consists of two phases: In first detection, the three-chambered box was empty, and the movement was not videotaped. In second detection, a perforated plastic box with a stimulus mouse (an unfamiliar C57BL/6J mouse) and an empty one were placed on the two side of the three-chambered box. The distance traveled, the duration spent and numbers of entrances in the three chambers were recorded for 5 min.

**Open field test**
The open field test (OFT) was used to assess the locomotion activity and exploratory behavior of rodents. Mice were placed in the center of an open field (44 cm × 44 cm × 30 cm), and after 30 s of adaptation, the distance traveled, the duration spent in the center numbers of entrances and rears were recorded during the final 5 min of the test.

**Elevated plus maze test**
The elevated plus maze test (EPM) was used to assess anxiety-like behavior in rodents. The maze was composed of two open arms (30 cm×6 cm) and two closed arms (30 cm × 6 cm × 15 cm). A central 6 cm × 6 cm square platform had access to all arms. Mice were placed in the center of the maze, habituated for 30 s and recorded the distance traveled, the number of entries and the duration in each arm in the next 5 min.

**Light/dark transition test**
The light/dark transition test was a method of evaluating anxiety-like behavior in rodents. Mice were placed in the light zone of an open field (20 cm×15 cm × 25 cm), which were same as the dark zone, except that the latter has a cover to keep away from light. The two zones were divided by a black plastic clapboard with a small hole to create optimum entryways. The distance and time traveled in light zone, numbers of transition were recorded during the 5 min testing.

**Y-maze**
The Y-maze was applied to evaluate spatial recognition memory in rodents. The Y-maze apparatus was composed of three arms (30 cm × 6 cm × 15 cm) intersecting at 120°. Mice were placed in the center of the maze and allowed to freely explore the three arms for 8 min. The sequence and total numbers of entering into three arms were noted. The percentage of spontaneous alternation (%) = ((number of alternations)/(total number of arm entries − 2)) × 100.
**Tail suspension test**

The TST was used to evaluate behavioral despair and reflected by the duration of immobility. Mice were individually suspended by their tails using a small piece of adhesive tape, which was placed 2 cm from the tip of the tail. The test lasted for 6 min. The duration of immobility was analyzed during the final 5 min. Animals were considered to be immobile only when they remained suspended passively and were completely motionless. A trained observer blinded to group recorded the total immobility time. This test was real-time monitored with a video surveillance system.

**Sample preparation**

After the behavioral tests, mice were killed by decapitation after anesthesia. The entire brain of each mouse was removed, and the HP and PFC tissues were separated. All tissues were quickly frozen in liquid nitrogen and then stored at −80 °C until analysis. After being accurately weighed, the brain sample was transferred into precooling EP tube and homogenized with 200 μl precooling ultra-pure water, and then added into 800 μl precooling methanol/acetonitrile solution (1:1, v/v) and vortex-mixed. Next, after 20 min ice-water bath ultrasonic extraction, the mixture was incubated at −20 °C for 1 h to precipitate protein, then was centrifuged at 14,000 × g, 4 °C for 20 min. The supernatant was transferred into a new EP tube and vacuum dried. Before the detection, 100 μl acetonitrile/H2O solution (1:1, v/v) was added to the dried extract to dissolve, and centrifuged at 14,000 × g, 4 °C for 20 min. Then the supernatant was used for the LC–MS/MS analysis.

**LC–MS/MS analysis**

LC–MS/MS was conducted with an Agilent 1290 Infinity chromatography system and AB SCIEX QTRAP 5500 mass spectrometer. In all, 10 mM ammonium acetate solution and acetonitrile were used as mobile phase A and B. The samples were placed in 4 °C automatic sampler with column temperature of 45 °C, and the flow rate was 0.3 mL/min and the injection volume was 2 μl. The gradient of mobile phase B was as follows: 0–18 min at 90–40% acetonitrile; 18–18.1 min at 40–90% acetonitrile and 18.1–23 min at 90%. Besides, the MS system was operated with a negative ion mode under the following conditions: ion sapary voltage floating, −4500 V; source temperature, 450 °C; ion source gas 1, 45; ion source gas 2, 45; curtain gas, 30. Analyses were determined by electrospray ionization using multiple reaction monitoring. Peak chromatographic area and retention time were analyzed with Multiquant software. The standard substance of energy metabolites was used to calculate the retention time and identify metabolites.

**RNA extractions, reverse transcription, and real-time quantitative PCR**

The HP and PFC samples stored at −80 °C were taken out to unfreeze. In all, 1 μg of RNA, isolated from the each tissue in TRIzol (Invitrogen, USA), was used for cDNA synthesis by PrimeScript RT reagent Kit (Takara, Japan) following the manufacturer’s protocol. SYBR gene detection system (Roche, Germany) was used to determine specific gene expression levels in each tissue. Each transcript value was calculated as the average of triplicate samples across experimental condition. Values were normalized to β-actin and GAPDH. Gene expression was calculated using the formula 2^−ΔΔt. The primers are shown in Supplementary Table S1.

**Western blotting**

The HP and PFC tissues were dissociated by radio-immunoprecipitation assay solution containing phosphatase inhibitor and protease inhibitor cocktail (Roche, Germany) and processed by ultrasound, finally centrifuged at 14,000 × g, 4 °C for 15 min and collected the supernatant to obtain the protein solution. The proteins in the sample were separated using a 10–12% SDS polyacrylamide gel, then transferred to polyvinylidene fluoride membrane (Millipore, USA) for blocking. The proteins were incubated with rabbit monoclonal anti-AKT1/2/3 (Abcam, ab179463,1:5000), rabbit monoclonal anti-phospho-AKT (Cell Signaling, #4060, 1:1000), rabbit monoclonal anti-CREB (Cell Signaling, #9197,1:1000), rabbit monoclonal anti-phospho-CREB (Ser133) (Cell Signaling, #8212, 1:1000), rabbit monoclonal anti-neurotrophic factor (BDNF) (Abcam, ab108319,1:1000), rabbit monoclonal anti-SDHc (Abcam, ab155999, 1:1000), rabbit monoclonal anti-Sucla2 (Abcam, ab183513, 1:5000), rabbit polyclonal anti-brain-derived neurotrophic factor (BDNF) (Abcam, ab108319,1:1000), rabbit monoclonal anti-GAPDH (Abcam, ab155999, 1:1000), rabbit monoclonal anti-β-tublin (Cell Signaling, ab181602,1:8000) overnight at 4 °C and subsequently incubated with secondary anti-rabbit antibodies (Bio-rad, cat# 170–6515,1:10,000) or secondary anti-mouse antibodies (Bio-rad, cat# 170–6516,1:10,000) for 2 h at room temperature. The signals were visualized using a chemiluminescence kit (Millipore, USA) and analyzed with Quantity one software (Bio-Rad, USA).

**Statistics**

All data were analyzed using SPSS 21.0 (IBM, USA) and values were considered significant at p < 0.05. The statistic differences among three groups were assessed by one-way analysis of variance (ANOVA) followed by Fisher’s least significant difference correction. Data were expressed as
mean ± SEM or mean. The results of statistical analyses were shown by Graphpad Prism 7.0 (San Diego, USA). Pearson’s correlation coefficient was applied to calculate the correlations between behaviors and metabolites in the HP and PFC.

Results

NBP administration prevents development of social avoidance in CSDS

As shown in the experimental approach schedule (Fig. 1a), we used the social interaction test to determine the efficacy of the CSDS model and determine whether NBP promotes resilience to CSDS in mice. We found lower SI ratios in the CSDS + PLA group than the CON + PLA group, but higher SI ratios in the CSDS + NBP group compared with the CSDS + PLA group (Fig. 1b). Of the mice showing defeat, a significantly higher proportion of NBP mice (80%) exhibited resilience to stress compared with PLA mice (30%) \((\chi^2 [1] = 5.051, p = 0.025)\) (Fig. 1c). Moreover, ANOVA detected a significant difference in interaction zone entries: post hoc comparisons showed that CSDS + PLA mice entered interaction zones less times than CON + PLA mice, whereas CSDS + NBP mice entered center zones more times than CSDS + PLA mice (Fig. 1d). Interestingly, as shown by time spent in interaction zones and typical tracks (Fig. 1f), CSDS + PLA mice spent less time in interaction zones compared with CON + PLA mice when a target CD1 was present. Conversely, there were no differences in time spent in interaction zones among the three groups when a target CD1 was absent (Fig. 1e).

NBP treatment ameliorates decreased body weight and increases sociability of CSDS

Before the defeat procedure, mice in all three groups showed no statistical difference in body weight, as expected. However, after 10 days of the defeat procedure, body weight was different among the three groups (Fig. 2a). Post hoc comparisons showed that mice in the CSDS + NBP group weighed more \((24.56 ± 1.47 \text{ g})\) compared with the CSDS + PLA group \((23.15 ± 0.81 \text{ g})\), whereas mice in the CON + PLA group \((24.18 ± 1.32 \text{ g})\) showed no difference compared with the other two groups. The SPT showed no significant differences in total distance among the three groups. Post hoc testing showed a reduced number of mice entering the stimulus mouse chamber in the CSDS + PLA group compared with the CON + PLA group. Meanwhile, the number increased in the CSDS + NBP group compared with the CSDS + PLA group (Fig. 2d).

NBP attenuates anxiety-like and despair behavior following CSDS

In the OFT, CSDS + PLA group mice showed less locomotion activity and anxiety-like behavior compared with CON + PLA group mice, reflected by a marked decrease in number of center zone entries and total distance (Fig. 2e, f). Interestingly, the CSDS + NBP group showed recovery of exploration and locomotion, reflected by an increase in number of center zone entries and total distance compared with the CSDS + PLA group (Fig. 2e, f). Nonetheless, NBP treatment did not affect time spent in the center zone or distance in the center zone and periphery zone or number of rears (Fig. 2g; Supplementary Fig. S2A–C). The EPM and light/dark transition test (see Supplementary Fig. S2D, E) are also widely used to examine anxiety. However, we found no significant differences in these tests. Simultaneously, we performed the TST to detect behavioral despair (Fig. 2h). Immobility time was significantly increased in the CSDS + PLA group compared with the CON + PLA group in the TST, whereas NBP-treated (CSDS + NBP) depressed mice showed less immobility time than PLA-treated (CSDS + PLA) depressed mice. In addition, we found no statistically significant differences in spatial working memory in the Y-maze test (see Supplementary Fig. S2F).

NBP treatment alters metabolite levels of energy metabolism pathways in the HP and PFC of mice

There were significant differences in the levels of target metabolites among the three groups in the HP and PFC. These differential metabolites are shown in Supplementary Table S2.

In the HP, compared with the CON + PLA group, thiamine pyrophosphate (TPP; Fig. 3a), dihydroxyacetone phosphate (DHAP; Fig. 3b), guanosine 5’-diphosphate (GDP; Fig. 3d), guanosine 5’-triphosphate (GTP; Fig. 3e), and succinate (Fig. 3f) were all significantly increased, whereas d-glucose-6-phosphate (d-G-6-P; Fig. 3c) was decreased in the CSDS + PLA group. In addition, guanosine monophosphate (GMP; Fig. 3g) showed a significant increase in the CSDS + NBP group compared with the CSDS + PLA group. Meanwhile GTP (Fig. 3e), succinate (Fig. 3f), oxaloacetate (Fig. 3h), nicotinamide adenine dinucleotide (NAD; Figs. 3i), 3-phospho-d-glycerate (3-P-d-G; Fig. 3j), and phosphoenolpyruvate (PEP;
Fig. 1 (See legend on next page.)
Fig. 3k) levels were significantly reduced in the CSDS + NBP group. There were no significant differences in other metabolites in the HP. In the PFC, citrate (Fig. 3l) and isocitrate (Fig. 3m) were reduced in the CSDS + PLA group compared with the CON + PLA group, while NAD (Fig. 3n) and nicotinamide adenine dinucleotide phosphate (NADP; Fig. 3o) were both significantly increased in the CSDS + PLA group. There were no significant differences in other metabolites in the PFC.

A total of 11 different metabolites were significantly altered in the HP. Compared with the CON + PLA group, five metabolites (TPP, DHAP, GDP, GTP, succinate) were increased and one metabolite (n-G-6-P) decreased in the CSDS + PLA group. Meanwhile six metabolites (GTP, succinate, NAD, PEP, oxaloacetate, 3-P-D-G) were decreased and one metabolite (GMP) increased in the CSDS + NBP group compared with the CSDS + PLA group. Further, a total of four different metabolites were significantly altered in the PFC. Compared with the CON + PLA group, two metabolites (citrate, isocitrate) were decreased and two metabolites (NAD, NADP) increased in the CSDS + PLA group. Among the differentially altered metabolites, only NAD was altered in both the HP and PFC, with the others metabolites altered in only one brain region (HP or PFC). This indicates that the altered metabolites show significant brain region specificities.

Differential metabolites in the HP and PFC correlate with behavior

Correlation analysis revealed that differential metabolites in the HP and PFC correlate with observed behavior (see Supplementary Fig. S3, S4). In the HP, a significantly negative association was shown between succinate levels and interaction zone SI ratio ($r = -0.565, p = 0.028$; Fig. S4a) and interaction zone entries ($r = -0.569, p = 0.027$; Fig. S4b). Negative association was also shown between GMP and novel object zone distance in the three-chambered test ($r = -0.561, p = 0.029$; Fig. S4c). Significant positive association was shown between 3-P-D-G levels and novel object zone distance in the three-chambered test ($r = 0.520, p = 0.047$; Fig. S4d). Similarly, positive association was shown between PEP levels and novel object zone distance in the three-chambered test ($r = 0.600, p = 0.018$; Fig. S4e). For oxaloacetate, there was positive association with stimulus mouse zone distance ($r = 0.578, p = 0.024$; Fig. S4f) and total distance ($r = 0.527, p = 0.043$; Fig. S4g) in the three-chambered interaction test. In the PFC, citrate showed a significantly negative association with novel object zone distance in the three-chambered test ($r = -0.525, p = 0.044$; Fig. S4h), but a positive association with interaction zone SI ratio ($r = 0.526, p = 0.044$; Fig. S4i). Reduced isocitrate levels after CSDS showed significant positive association with reduced center zone distance in the OFT ($r = 0.668, p = 0.006$; Fig. S4j).

NBP treatment alters gene expression of TCA enzymes and purinergic receptors in the HP and PFC

Gene expression levels of key TCA cycle enzymes and purinergic receptors were tested by RT-qPCR. In the HP, mRNA levels of SDHc (Fig. 4a) and ligand-gated ion channel 1 of purinergic receptor P2X (P2rx1; Fig. 4c) were significantly increased in the CSDS + NBP group compared with the CSDS + PLA group. Meanwhile, mRNA levels of the beta subunit of succinate-coenzyme A ligase, GDP-forming (Sucla2-GDP) were reduced in the CSDS + NBP group compared with the CSDS + PLA group (Fig. 4a). In the PFC, transcription of citrate synthase (CS) was significantly reduced in the CSDS + NBP group compared with the CSDS + PLA group (Fig. 4b). Alternatively, there were no significant differences in purinergic receptor genes in the PFC (Fig. 4d). We also examined expression of stress-related and serotonin-related genes, but found no statistically significant change in either the HP or PFC (see Supplementary Fig. S5).

NBP administration increases protein expression of AKT/CREB in the HP

Protein expression levels of AKT, phospho-AKT, CREB, and phospho-CREB were detected by western blotting. In the HP, we found significantly increased expression of p-AKT, p-AKT/akt (Fig. 4e), and p-CREB (Fig. 4d) in the CSDS + NBP group compared with the CSDS + PLA group. In the PFC, p-CREB levels were increased in the CSDS + PLA group compared with the CON + PLA group, whereas the CSDS + NBP group showed a marked reduction in p-CREB levels (Fig. 4h) compared with the
CSDS group. Protein expression of SDHc, Sucla2, P2rx1, BDNF, and Trkb was also detected in the HP and PFC, but no significant differences were found among the three groups (see Supplementary Fig. S6, S7).

Discussion

MDD is a common debilitating mental disorder and its etiology is complex and still unknown. Alterations of the HPA axis, hypofunction of monoamine neurotransmitters and glutamatergic system42, changes in synaptic plasticity43, and disturbances in amino-acid metabolism44 and lipid metabolism45 have been implicated in the pathogenesis of depression. Comparing the metabolic profiles of patients with MDD, CSDS models and antidepressant of our previous study (see Supplementary Fig. S8) suggested perturbations of energy metabolism have been linked to depression, however, whether modulating energy metabolism may prevent development of the disorder and the possible underlying molecular mechanisms are not known. In our study, we found that NBP treatment ameliorated stress-induced behavioral deficits, which may affect energy metabolism in the brain by regulating the AKT/CREB signaling pathway.

CSDS model is the type of stress consisting of a mixture of physical and psychological components and it shows predictive validity to responds chronic administration of antidepressants46,47. According to the standardized protocol for CSDS in mice, the SI test is used to evaluate whether the model was built successfully, and reduction of SI ratio in defeated mice could reflect the success of the CSDS model in the present study. Surprisingly, we found that NBP administration prevented development of social avoidance, which significantly increased SI ratio in the SI test. Similar results were found in the three-chambered interaction test, which was used to examine sociability in mice. Total distance and number of entries into the stimulus mouse zone were markedly increased after NBP treatment, showing that mice treated with NBP exhibit an increase of exploration and sociability. The SPT is commonly used in assessment the anhedonia of MDD model, whereas the sucrose preference showed no significant difference in our study. Similarly, several previous experiments in our and other groups also found no difference in sucrose preference after the CSDS procedure40,47,50,51. Sucrose preference has also been shown to be prone to bias, because taste and smell disturbances, context of liquid intake, and group comparisons can all modify the preference index50. In this study, it may be the intragastric administration that affect the taste and smell and cause the sucrose preference unaffected in a stressful situation. The OFT is applied to analyze locomotion and anxiety-like behavior in rodents52,53. NBP administration significantly increased total distance traveled, indicating amelioration of locomotion deficits. In addition, in the OFT, there was an increase in number of center zone entries in the NBP-treated mice, suggesting NBP promoted greater exploratory behavior and ameliorated anxiety-like behavior. However, NBP did not influence other anxiety-related behaviors, such as the EPM and light/dark transition test. Therefore, NBP may have a partial anxiolytic effect. After NBP treatment, immobility time decreased in the TST, indicating that NBP impacts despair behavior in mice.

Metabolomics is a widely used tool for exploring molecular pathways underlying symptoms of depression.
and recovery after pharmacotherapy. Levels of energy metabolism-associated metabolites were significantly perturbed in the social defeat mice. A similar disturbance of energy metabolism was also found in our previous studies in chronic unpredictable mild stress, learned helplessness, and chronic restraint stress model. The altered metabolites of energy metabolism pathway are involved in glycolysis and the TCA cycle. Glycolysis, beginning with the phosphorylation of glucose as the primary carbon source, is coupled to the TCA cycle to fully oxidize glucose and supply energy for the brain. Decreased D-G-6-P levels observed in the HP of defeated mice may result from a reduction of brain glucose uptake, which has also been shown in our previous studies of MDD. Lower levels of D-G-6-P indicate decreased upstream glucose and reduced glycolysis, which is consistent with the changed metabolism of Borna disease virus laboratory Strain V (BDV Strain V) infected rat cortical neurons from our group’s previous study. However, in the virus study, D-G-6-P and other upstream sugars were increased in a natural human strain BDV Hu-H1 cells. These inconsistent results reflected divergent effects of the two virus strains upon glucose metabolism in rat cortical neurons. DHAP and glyceraldehyde 3-phosphate are isomeric, and can transform one another using triose phosphate isomerase. Increased content of DHAP in defeated mice indicates decreased consumption of glyceraldehyde 3-phosphate, suggesting that the glycolysis process is inhibited in defeated subjects. TPP is a coenzyme of the pyruvate dehydrogenase complex, which catalyzes pyruvate oxidation decarboxylation to form acetyl CoA, which enters the TCA cycle. In our research, TPP levels were increased in stress-treated mice, which may provide an explanation for greater carbon flux through the TCA cycle. Levels of TCA metabolite (e.g., succinate, GDP, and GTP) showed significant upregulation in defeated mice in the HP. Succinate is the metabolic component after succinyl CoA synthetase (Sucl2) activity, and a precursor to succinate dehydrogenase (SDH) (Fig. 5). Sucl2 catalyzes the conversion of succinyl CoA into succinate, which is accompanied by generation of GTP via substrate level phosphorylation. This finding is consistent with increased levels of urinary succinate in MDD from our previous study, which may indicate that during depression, individuals consume greater carbon through the TCA cycle. And lower levels of glycolytic intermediates and upstream sugars in conjunction with higher of TCA intermediates indicate an equilibrium shift away from glycolysis and increased carbon flux through the TCA cycle, like the finding in the aforementioned research of BDV Strain V. While, in Hu-H1-infected neurons, lower levels of glycolytic and TCA intermediates combined with higher upstream sugar levels indicated a shift towards gluconeogenesis. These previous results may imply that virus strains might affect different metabolic pathways and elucidating the differences in specific

![Fig. 3 Differential target metabolites in the hippocampus and prefrontal cortex of CSDS model mice.](image-url)
Fig. 4 (See legend on next page.)
mechanisms requires further investigation. Furthermore, we found significantly decreased citrate and isocitrate levels in the PFC of the defeated group. Citrate and isocitrate are upstream metabolites of the TCA cycle. Reductions may indicate that the process is down-regulated in the PFC of defeated mice. Initial studies by our group found that citrate was differentially expressed in male patients with MDD compared with corresponding healthy controls. This was not found in female patients with MDD. This suggests that citrate could be used as a sex-specific urinary metabolite biomarker for diagnosing MDD.

We observed an increase in the glycolysis process with chronic treatment of NBP. Generation of 3-P-D-G is a reversible reaction catalyzed by phosphoglycerate kinase. Alteration of downstream metabolites suggests that NBP treatment might affect glycolysis. Conversion of PEP to pyruvate is catalyzed by pyruvate kinase along with generation of ATP, which is the last step in glycolysis. Downregulation of PEP suggests that the step is enhanced to generate more pyruvate and energy production after NBP treatment. Based on a candidate drug analysis, a recent review suggested that pyruvate may be a candidate drug for the treatment of MDD. Together with changes in diverse glycolytic metabolites, this also suggests that improvement of glycolysis might be the molecular mechanism responsible for the antidepressant-like effect of NBP. Simultaneously, we found decreased TCA cycle intermediate levels after NBP treatment. Significantly decreased levels of succinate and GTP and increased precursor (i.e., GMP) are consistent with decreased levels of succinate and GTP and increased SDHc gene expression levels. The alterations of downstream metabolites suggest that NBP treatment might affect glycolysis. Alteration of glycolytic intermediates is considered to be a coenzyme of many dehydrogenases with crucial roles in energy metabolism and electron transfer. Reduction of NAD may indicate that enzyme activity and electron transfer are decreased. In addition, oxaloacetate levels (which competitively inhibit SDH in the brain) were significantly decreased after NBP treatment. Reduction of oxaloacetate levels might compensate for a decrease in SDH activity. Thus, we can conclude that chronic pre-treatment with NBP might decrease metabolite levels to generate less carbon through the TCA cycle and achieve a natural recovery. Regulation of aerobic glycolysis and the TCA cycle is the consequence of energy adaptations. With sufficient energy, aerobic oxidation is reduced to save resources. These results were found with paroxetine treatment and ketamine treatment.

Besides enzymes in the TCA cycle, we also detected expression of P2X receptors, cation channels gated by ATP, to determine whether purinergic receptors are involved in metabolite responses. Interestingly, mRNA levels of Sucla2-GDP, SDHc, and P2rx1 were significantly altered in the HP, but protein levels showed no significant variation. This may be owing to the regulation of transcriptional or post-translational protein modification, and it may require the increase sample size and other protein-based techniques to validate in further study. Moreover, this finding might also indicate the increased glucose uptake and decreased TCA cycle metabolite levels are not merely regulated by altered TCA cycle enzymes and purine receptors levels.

Recent studies have reported that NBP exerts antioxidant, anti-inflammation, and anti-apoptosis through regulation PI3K/AKT/Nrf2 activation and possible inhibition TLR4/NF-kB signaling pathway. However, the signaling pathways involved in NBP administration in regulating the metabolism have not yet been elucidated. AKT/CREB is a classical signaling pathway involved in numerous biological processes. AKT plays a central role in the regulation of energy metabolism via mechanisms involving, but not fully restricted to, the cellular uptake and utilization of glucose. The phosphorylation and activation of AKT leads to a cascade of insulin signaling events that coordinate trafficking of glucose transporters (GLUT) to the plasma membrane. The similar results have been observed in the studies of human cancers. The increased capacity for glucose transport results in increased glucose-6-phosphate (G-6-P) availability for utilization in glycolysis and the pentose phosphate pathway (PPP). Another study has shown that AKT phosphorylates and activates phosphofructokinase-2 (PFK2), which is the sole enzyme responsible for the production and degradation of fructose-2, 6-bisphosphate (F-2, 6-BP). F-2,6-BP is not directly involved in the glycolysis, but it allosterically activates PFK-1 more potently than its own
product, fructose 1,6-bisphosphate (F-1,6-BP). By analogy with glycolysis, emerging evidence suggests that increased AKT may also affect oxidative metabolism. AKT indirectly promotes oxidative phosphorylation via increased formation of and access to glycolysis-derived substrates essential for TCA cycle activity and oxidative phosphorylation (e.g. pyruvate, ADP, NADH). CREB, phosphorylated by AKT at Ser133, is a key regulator of various intracellular processes including proliferation, differentiation, survival, neurogenesis, and neuronal plasticity. CREB has been investigated as a metabolic sensor and regulator of glucose homeostasis in the hippocampus (HP), whereas CREB activation by synaptic activity induces the expression of the GLUT3 and promotes Siah2-mediated stabilization of the hypoxia-inducible factor 1α (HIF-1α) that upregulates the expression of glycolysis genes. In addition, previous studies have shown that NBP can exert actions through the AKT/CREB signaling pathway. L-3-n-butylphthalide (NBP) stimulates proliferation, migration, and differentiation of hippocampal neural stem cells in amyloid precursor protein/presenilin 1 (APP/PS1) mice by activating the AKT/CREB signaling pathway. NBP promotes neurogenesis and neuroplasticity in cerebral ischemic rats via AKT-CREB signaling. In the present study, we observed an increase in expression of p-AKT and p-CREB after NBP treatment in the HP, whereas expression of p-CREB was reduced in the PFC after NBP administration. Consequently, this may suggest that NBP alters energy metabolism in the HP and PFC via regulation of the AKT/CREB signaling pathway. A limitation of our study was the incomplete validation of the potential mechanism of NBP on depression, that is to say, the other signaling mechanisms involved in the effect of NBP on energy metabolism did not be included. On this basis, we may make investigation in further studies. Together, NBP effectively attenuates CSDS-induced social deficits, anxiety-like behavior, and despair behavior. Targeted metabolomics profiling of the HP and PFC revealed that NBP alters metabolite levels of glycolysis and TCA cycle components. NBP also activated AKT and CREB phosphorylation to affect energy metabolism. Altogether, our results show that NBP can exert antidepressant effects.
by regulating energy metabolism via the AKT/CREB signaling pathway. Our findings provide the first evidence that NBP has antidepressant effects and yield important insights into the molecular energy metabolism changes underlying the therapeutic actions of NBP, thereby aiding research of novel antidepressant drugs.

Acknowledgements
This work was supported by the National Key R&D Program of China (Grant No. 2017YFA0902500), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (Grant No. 2019PT320002), the National Natural Science Foundation of China (Grant No. 81901398), and the Natural Science Foundation of Chongqing, China (Grant No. cstc2019jcyj-msxmX0025).

Author details
1NHIC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China. 3Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 4Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 5Chongqing Key Laboratory of Neurobiology, Chongqing, China. 6Chongqing Key Laboratory of Cerebrovascular Disease Research, Chongqing, China

Conflict of interests
The authors declare no conflicts of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41398-020-0731-z).

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41398-020-0731-z).

Received: 27 August 2019 Revised: 3 January 2020 Accepted: 13 January 2020
Published online: 03 February 2020

References
1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 743-800 (2015).
2. World Health Organization. Depression and other common mental disorders: global health estimates. Available at: http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-2017 (2017).
3. Mälli, G. S. & Mann, J. J. Depression. Lancet 392, 2299–2312 (2018).
4. Gartlehner, G. et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann. Intern. Med. 155, 772–785 (2011).
5. Moret, C., Isaac, M. & Bleyl, M. Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J. Psychopharmacology 23, 967–974 (2009).
6. Li, B. et al. Metabolite identification in fecal microbiota transplantation mouse livers and combined proteomics with chronic unpredictable mild stress mouse livers. Transl Psychiatry 8, 84 (2018).
7. Rao, C. et al. Hypothalamic proteomic analysis reveals dysregulation of glutamate balance and energy metabolism in a mouse model of chronic mild stress-induced depression. Neurochem. Res. 41, 2443–2456 (2016).
8. Shao, W. H., Chen, J. J., Fan, S. H., Yang, L. & Xie, P. Combined metabolomics and proteomics analysis of major depression in an animal model perturbed energy metabolism in the chronic mild stressed rat cerebellum. Omics J. Integr. Biol. 19, 383–392 (2015).
9. Yang, Y. et al. Proteomics reveals energy and glutathione metabolic dysregulation in the prefrontal cortex of a rat model of depression. Neuroscience 247, 191–200 (2013).
10. Qin, Y. et al. Chronic mild stress leads to aberrant glucose energy metabolism in depressed Macaca fascicularis models. Psychoneuroendocrinology 107, 59–69 (2019).
11. Koponen, H., Kaatus, H., Leppänen, E., Mäntyselkä, P. & Vanhala, M. Association between suicidal behaviour and impaired glucose metabolism in depressive disorders. BMC Psychiatry 15, 163 (2015).
12. Dong, M. X. et al. Integrated analysis reveals altered lipid and glucose metabolism and identifies NOTCH2 as a biomarker for parkinson’s disease related depression. Front. Mol. Neurosci. 11, 257 (2018).
13. Peng, Z. et al. Plasma metabolomics as a novel diagnostic approach for major depressive disorder. J. prototype Res. 11, 1741–1748 (2012).
14. Zheng, P. et al. Identification of urinary metabolite biomarkers for major depressive disorder. Mol. Cell Proteomics 12, 207–214 (2013).
15. Bai, S. et al. Brain region-specific metabolite networks regulate antidepressant effects of venlafaxine. Rsc Adv. 7, 46358–46369 (2017).
16. Wu, Y. et al. Metabolomic analysis reveals metabolic disturbances in the prefrontal cortex of the lipopolysaccharide-induced mouse model of depression. Behav. Brain Res. 308, 115–127 (2016).
17. Maes, M. et al. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20, 127–150 (2012).
18. Allen, J., Romay-Tallon, R., Brymer, K. J., Caruncho, H. J. & Kalynchuk, L. E. Mitochondria and mood: mitochondrial dysfunction as a key player in the manifestation of depression. Front. Neurosci. 12, 386 (2018).
19. Liu, C. L. et al. dl-3-n-butylphthalide prevents stroke via improvement of cerebral microvessels in Prrhs.p. J. Neurol. Sci. 260, 106–113 (2007).
20. Ying, P. et al. L-3-n-butylphthalide regulates amyloid precursor protein processing by PKC and MAPK pathways in SK-N-SH cells over-expressing wild type human APP695. Neurosci. Lett. 487, 211–216 (2011).
21. Feng, X., Peng, Y., Liu, M. & Cui, L. DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology 62, 1004–1010 (2012).
22. Li, L. et al. DL-3-n-butylphthalide protects endothelial cells against oxidative/nitrosative stress, mitochondrial damage and subsequent cell death after oxygen glucose deprivation in vitro. Brain Res. 1290, 91–101 (2009).
23. Chang, Q. & Wang, X. L. Effects of chiral 3-n-butylphthalide on apoptosis induced by transient focal cerebral ischemia in rats. Acta Pharmacol. Sin. 24, 796–804 (2003).
24. He, W., Zhou, W. & Hu, Z. Chinese herbal extract dl-3-n-butylphthalide A commonly used drug for the treatment of ischemic stroke as a novel therapeutics are used for treating degenerative diseases. Neural Regen. Res. 06, 1590–1593 (2011).
25. Lei, H., Zhao, C. Y., Liu, D. M., Zhang, Y. & Peng, Y. L. 3-n-Butylphthalide attenuates β-amyloid-induced toxicity in neuroblastoma SH-SY5Y cells through regulating mitochondria-mediated apoptosis and MAPK signaling. J. Asian Nat. Prod. Res. 16, 11 (2014).
26. Fernandez-Moriano, C., Gonzales-Burgoes, E. & Gomez-Serranillos, M. P. Mitochondria-targeted protective compounds in Parkinson’s disease. Oxid. Med. Cell Longev. 2015, 409827 (2015).
27. Xiong, N. et al. DL-3-n-butylphthalide, a natural antioxidant, protects dopaminergic neurons in rotenone models for Parkinson’s disease. Neurobiol. Aging 33, 1777–1791 (2012).
28. Villa, R. F., Ferrari, F. & Moretti, A. Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol. Ther. 184, 131–144 (2018).
29. Robey, R. B. & Hay, N. Is Akt the “Warburg kinase”? Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol 19, 25–31 (2009).
30. Schulze, S. M., Hemmings, B. A., Markus, N. & Oliver, T. PKB/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev. Mol. Med. 14, e1 (2012).
31. Morales-Ruiz, M., Santel, A., Ribera, J. & Jiménez, W. The role of Akt in chronic liver disease and liver regeneration. Semin. Liver Dis. 35, 081–016 (2017).
32. Kohn, A. D., Summers, S. A., Birnbaum, M. J. & Roth, R. A. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose
uptake and glucose transporter 4 translocation. J. Biol. Chem. 271, 31372–31378 (1996).
33. Revathidevi, S. & Munirajan, A. K. Akt in cancer: mediator and more. Semin. Cancer Biol. 59, 80–91 (2019).
34. Gottlob, K. et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15, 1406–1418 (2001).
35. Blu, C. et al. Feature article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc. Natl. Acad. Sci. USA 110, 12526–12534 (2013).
36. Du, K. CREB is a regulatory target for the protein kinase Akt/PKB. J. Biol. Chem. 273, 32377–32379 (1998).
37. Wang, C. Y. et al. DL-3-n-butylphthalide-induced upregulation of antioxidant defense is involved in the enhancement of cross talk between CREB and Nrf2 in an Alzheimer's disease mouse model. Neurobiol. Aging 38, 32–46 (2016).
38. Golden, S. A., Covington, H. E., Berton, O. & Russo, S. J. A standardized protocol for repeated social defeat stress in mice. Nat. Protoc. 6, 1193–1191 (2011).
39. Golden, S. A., Covington, H. E., Berton, O. & Russo, S. J. Corrigendum: a standardized protocol for repeated social defeat stress in mice. Nat. Protoc. 10, 643 (2015).
40. Bai, S. et al. Insight into the metabolic mechanism of Diterpene Ginkgolides on antidepressant effects for attenuating behavioural deficits compared with venlafaxine. Sci. Rep. 7, 5901 (2017).
41. Wang, W. et al. Targeted metabolomic pathway analysis and validation revealed glutamatergic dysfunction in the prefrontal cortex among the chronic social defeat stress mice model of depression. J. Proteome Res. 15, 3784–3792 (2016).
42. Olivier, O. et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311, 864–868 (2006).
43. Jiang, X., Lin, W., Cheng, Y. & Wang, D. mGluR5 facilitates long-term synaptic depression in a stress-induced depressive mouse model. Curr. J. Psychiatry. 706/7437/19874162, https://doi.org/10.1177/0706743719874162 (2019).
44. Je, J. et al. Memory impairment induced by borona disease virus 1 infection is associated with reduced H3K9 acetylation. Cell Physiol. Biochem. 49, 381–394 (2010).
45. Lei, Y., Li, D., Deng, J., Shao, W. H. & Xie, P. Metabolomic profiling of three brain regions from a postnatal infected Borna disease virus Hu-H1 rat model. Metabolomics 10, 484–495 (2013).
46. Liu, Y. et al. Social defeat stress causes depression-like behavior with metabolite changes in the prefrontal cortex of rats. PLoS ONE 12, e0176725 (2017).
47. He, Y. et al. iTRAQ-based proteomics suggests LRPS6, NPY and NPY2R perturbation in the hippocampus involved in CSDS may induce resilience and susceptibility. Life Sci. 211, 102–117 (2018).
48. Krishnan, V. & Nestler, E. J. The molecular neurobiology of depression. Nature 453, 894–902 (2008).
49. Miczek, K. A., Yap, J. J. & Covington, H. E. Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake. Pharmacol. Ther. 120, 102–128 (2008).
50. Herniques-Abes, A. M. & Queiruz, C. M. Ethological evaluation of the effects of social defeat stress in mice beyond the social interaction ratio. Front. Behav. Neurosci. 9, 364 (2015).
51. Bondar, N. P., Kovalenko, I. L., Avgustinovich, D. F., Smagin, D. A. & Kuryavtseva, N. N. Anhedonia in the shadow of chronic social defeat stress, or When the experimental context matters. Open Behav. Sci. J. 3, 17–27 (2008).
52. Kraeuter, A. K., Guest, P. C. & Samyai, Z. The open field test for measuring locomotor activity and anxiety-like behavior. Methods Mol. Biol. 1916, 99–103 (2016).
53. Prut, L. & Belzung, C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 463, 3–33 (2003).
54. Liang, Z. et al. GC-MS-based metabolomic study on the antidepressant-like effects of diterpene ginkgolides in mouse hippocampus. Behav. Brain Res. 314, 116–124 (2016).
55. Bai, S. et al. 1H NMR-based metabolic profiling reveals the effects of fluoxetine on lipid and amino acid metabolism in astrocytes. Int. J. Mol. Sci. 16, 8490–8504 (2015).
56. Berger, R. D. et al. Metabolomics enables precision medicine: “A White Paper, Community Perspective”. Metabolomics 12, 149 (2016).
57. Yang, L. N. et al. Integrated metabolomics and proteomics analysis revealed second messenger system disturbance in hippocampus of chronic social defeat stress rat. Front. Neurosci. 13, 247 (2019).
58. Liu, L. et al. Hippocampal metabolic differences implicate distinctions between physical and psychological stress in four rat models of depression. Transl. Psychiatry 8, 4 (2018).
59. Detka, J. et al. Brain glucose metabolism in an animal model of depression. Neuroscience 295, 198–208 (2015).
60. Liu, S. et al. GC-MS-based metabolonomic profiling displayed differing effects of Borna disease virus natural strain Hu-H1 and laboratory strain V infection in rat cortical neurons. Int. J. Mol. Sci. 16, 19347–19368 (2015).
61. Zheng, P. et al. Identification of sex-specific urinary biomarkers for major depressive disorder by combined application of NMR- and GC-MS-based metabonomics. Transl. Psychiatry 6, e6955 (2016).
62. MacDonald, K. et al. Biomarkers for major depressive and bipolar disorders using metabolomics: a systematic review. Ann. J. Med. Genet. B Neuropsychiatr. Genet. 180, 122–137 (2019).
63. Stepanova, A., Shurubor, V., Valsecchi, F., Manfredi, G. & Galkin, A. Differential susceptibility of mitochondrial complex II to inhibition by oxaloacetate in brain and heart. Biochim. Biophys. Acta 1857, 1561–1568 (2016).
64. Webhofer, C. et al. Proteomic and metabolomic profiling reveals time-dependent changes in hippocampal metabolism upon paroxetine treatment and biomarker candidates. J. Psychiatr. Res. 47, 289–298 (2013).
65. Weckmann, K., Labermaier, C., Asara, J. M., Müller, M. B. & Tuck, C. W. Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates. Transl. Psychiatry 4, e481 (2014).
66. Qiu, H., Ma, J., Wu, H. & Ding, C. DL-3-n-butylphthalide improves ventricular function, and prevents ventricular remodeling and arrhythmias in post-MI rats. Naunyn Schmiedebergs Arch. Pharmacol. 391, 627–637 (2018).
67. Qi, Q. et al. DL-3-n-butylphthalide alleviates vascular cognitive impairment induced by chronic cerebral hypoperfusion by activating the Akt/Nrf2 signaling pathway in the hippocampus of rats. Neuosci. Lett. 672, 59–64 (2018).
68. Yang, M. et al. DL-3-n-butylphthalide improves lipopolysaccharide-induced depression-like behavior in rats: involvement of Nrf2 and NF-kB pathways. Psychopharmacology 235, 2573–2585 (2018).
69. Waski, A. A. & Lehtonen, S. Glucose transporters in diabetic kidney disease-friends or foes? Front. Endocrinol. (Lausanne) 9, 155 (2018).
70. Kang, J., Ge, C., Yu, L., Li, L. & Ma, H. Long-term administration of dehydropiandrosterone accelerates glucose catalolism via activation of PI3K/Akt-PP2 signaling pathway in rats fed a high-fat diet. PLoS ONE 11, e0159077 (2016).
71. Jr, K. J., Han, H. S., Kim, M. J. & Koo, S. H. CREB and FoxO1: two transcription factors for the regulation of hepatic gluconeogenesis. BMJ Rep. 46, 567–574 (2013).
72. Segarra-Mondejar, M. et al. Synaptic activity-induced glycolysis facilitates membrane lipid provision and neurite outgrowth. EMBO J. 37, https://doi.org/10.15252/emboj.201797368 (2018).
73. Lei, H. et al. L-3-n-butylphthalide regulates proliferation, migration, and differentiation of neural stem cell in vitro and promotes neurogenesis in APP/P51 mouse model by regulating BDNF/TbK/CREB/Akt pathway. Neurotox. Res. 34, 477–488 (2018).
74. Yang, L. C. et al. L-3-n-butylphthalide promotes neurogenesis and neuronplasticity in cerebral ischemic rats. CNS Neurosci. Ther. 21, 733–741 (2015).